Form 4 for JAZZ Jazz Pharmaceuticals plc
Accepted 2024-01-19 00:00:00 ET · period of report 2024-01-17 · accession 0001784606-24-000004 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-01-19 | 2024-01-17 | JAZZ | COZADD BRUCE C | COB, CEO, Dir | A - Grant | $0.00 | +26.5K | 414.3K | +7% | $0 | |
| 2024-01-19 | 2024-01-17 | JAZZ | COZADD BRUCE C | COB, CEO, Dir | F - Tax | $119.13 | -12.2K | 402.1K | -3% | -$1.46M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2024-01-17 | A | A | 26,545 | $0.00 | 414,303 | D | — | — | (F2) The Reporting Person acquired 137 ordinary shares and 37 ordinary shares under a Section 423 Employee Stock Purchase Plan on May 31, 2023 and November 30, 2023, respectively. |
| 2 | Common | Ordinary Shares | 2024-01-17 | F | D | 12,245 | $119.13 | 402,058 | D | — | — |